ObjectiveGI Secures Series A Funding Led by Frist Cressey Ventures

Contacts:
Colleen Hoke, ObjectiveGI
colleen.hoke@objectivegi.com

Jillian Hammell, Crowley Webb
jillian.hammell@crowleywebb.com
716.856.2932 x237

ObjectiveGI Secures Series A Funding Led by Frist Cressey Ventures
The clinically integrated ancillary care platform will accelerate expansion into local gastroenterology (GI) practices to provide specialized care for the rising NonAlcoholic SteatoHepatitis (NASH) epidemic

NASHVILLE, TN, December 20, 2019 – ObjectiveGI, the integrated research and technology services platform company, announced today it has closed a Series A funding round led by Frist Cressey Ventures with participation from other new and existing investors. With the investment, Frist Cressey Ventures partners Chris Booker and Navid Farzad will join the ObjectiveGI Board of Directors.

ObjectiveGI is a physician partnership model that seamlessly integrates gastroenterology (GI) research services into local community-based GI practices in support of patient care and practice enhancement, offering research infrastructure, optimal trial selection, study implementation and key research personnel management. On the heels of opening its 10th Center of Research Excellence earlier in 2019, this funding will help ObjectiveGI double the number of clinically integrated research sites by the end of 2020, expanding its transformative presence while driving meaningful partnerships and improving patient outcomes for those affected by NASH.

“ObjectiveGI offers a different approach to research aimed at improving patient outcomes through our partnerships with leading GI physicians,” said Colleen Hoke, president and CEO, ObjectiveGI. “It’s an exciting time to be in healthcare and support science at the point of care, and we look forward to scaling and growing our business to expand our impact for patients across the country.”

“Frist Cressey Ventures is dedicated to supporting and strategically investing in partners that provide the greatest value to patients and society as a whole. In the face of the growing need for impactful NASH research, ObjectiveGI is uniquely positioned to improve healthcare and patient outcomes,” said former U.S. Senate Majority Leader Senator Bill Frist, M.D., co-founder and partner, Frist Cressey Ventures. “We are proud to support ObjectiveGI as they continue to advance emerging care solutions for NASH patients.”

Since launching the first Center of Research Excellence in 2018, ObjectiveGI and its partners have supported value-based care initiatives for more than 3,000 patients. Today, these centers can be found on-site at GI practices located in Alabama, Arkansas, Florida, Maryland, Michigan, North Carolina, South Carolina and Tennessee.

About ObjectiveGI
ObjectiveGI, Inc., is an integrated research and technology services platform company that establishes “Center of Research Excellence” partnerships with gastroenterology physician practices, providing research infrastructure, optimal trial selection, study implementation and key research personnel management. Its proprietary processes and technology eliminate the healthcare workflow disruptions commonly associated with clinical trials, thus enabling the delivery of a valuable ancillary vertical that transforms care and improves health outcomes. ObjectiveGI’s initial focus is NonAlcoholic SteatoHepatitis (NASH), a silent chronic disease that affects millions of Americans. Learn more about ObjectiveGI at www.ObjectiveGI.com

About Frist Cressey Ventures
Frist Cressey Ventures (FCV) is dedicated to accelerating the growth of high-potential healthcare enterprises through value-added partnerships. FCV invests in healthcare services and information technology businesses that provide meaningful solutions to improve quality of care, patient outcomes and efficiency in the delivery of services. FCV joins like-minded entrepreneurs who share the same core values in their pursuit to improve healthcare. For more information, please visit www.fcventures.com.